Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8IWT1
UPID:
SCN4B_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IWT1; E9PPT5; Q6PIG5
Background:
The Sodium channel subunit beta-4, encoded by the gene with accession number Q8IWT1, plays a crucial role in modulating channel gating kinetics. It is instrumental in causing negative shifts in the voltage dependence of activation of certain alpha sodium channels, without affecting their inactivation. This protein also modulates the susceptibility of sodium channels to inhibition by various toxic peptides from spider, scorpion, wasp, and sea anemone venom.
Therapeutic significance:
Sodium channel subunit beta-4 is linked to significant cardiovascular conditions, including Long QT syndrome 10 and familial atrial fibrillation 17. These diseases underscore the protein's critical role in cardiac electrical activity and rhythm regulation. Understanding the role of Sodium channel subunit beta-4 could open doors to potential therapeutic strategies for these life-threatening conditions.